drugset / Trial / NCT07407660
Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax
Phase 3
Not yet recruiting
250 enrolled
Peking University People's Hospital
Shanghai Qianzhanruiji Enterprise Consulting Co., Ltd. · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to compare the efficacy and safety of a shortened treatment course based on the bone marrow blast count on Day 14 versus standard treatment in patients with acute myeloid leukemia treated with venetoclax plus azacitidine.
Timeline
- Start
- 2026-02-01
- Primary completion
- 2028-02-01
- Completion
- 2030-02-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Venetoclax | Small molecule | — | — |